학술논문
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
Document Type
Article
Source
In Leukemia Research April 2019 79:27-33
Subject
Language
ISSN
0145-2126